ALKBH5 and cardiomyopathy: Recent studies have noted increased mortality in ALKBH5-deficient mice, whereas overexpression of ALKBH5 modulates Rasal3 mRNA stability in an m6A-dependent manner, activating the RAS/RAF/ERK pathway to inhibit CMs apoptosis and alleviate doxorubicin-induced cardiomyopathy (DIC) [139].